Buying guide

Versius vs da Vinci (and Ion) in 2026

Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.

Key differences

On DEPLOY's record, da Vinci (and Ion) is further along: at the production stage versus Versius at the commercial stage, as of 2026.

Versius has the lower recorded price.
da Vinci (and Ion) has more verified real-world deployments (13 vs 4).
Versius is at the commercial stage; da Vinci (and Ion) at the production stage.

Attribute	Versius View full model page →	da Vinci (and Ion)View full model page →
Manufacturer	CMR Surgical	Intuitive Surgical
Form factor	surgical	surgical
Maturity	commercial	production
Autonomy	◐ not independently verified	◐ not independently verified
Availability	internal-onlyenterprise	internal-onlyenterprise
Price	$750,000-$1,000,000 (analyst estimate)	$1,800,000-$2,500,000 (analyst estimate) or $1,500,000-$2,500,000 (actual sale price)
Capability claims	Assists surgery (teleoperated-assisted, claimed)	Assists surgery (teleoperated-assisted, verified)
Brain	—	—
Verified deployments	4	13
Privacy practices	—	—
Sources on file	24	29

Track this matchup

Get told the moment Versius or da Vinci (and Ion) changes. Verified changes only, the second they are real. No press-release noise.

Versius

da Vinci (and Ion)

Editorial summaries

Versius

CMR Surgical's Versius (and Versius Plus) is a modular, multi-arm, soft-tissue minimal-access surgical robot from UK-based CMR Surgical, and the international-soft-tissue archetype of DEPLOY's surgical cluster. Its modular multi-arm architecture is a deliberate contrast to the monolithic design of Intuitive's da Vinci: it is teleoperated and software-driven, capturing telematic, video, and outcome data.

On regulatory status (a correction worth recording): Versius is US-FDA-cleared for cholecystectomy via a De Novo authorization in October 2024, with Versius Plus cleared via 510(k) on December 18, 2025 (also cholecystectomy) and a gynecology 510(k) submitted April 29, 2026 (pending); it is not broadly 'US-pending', only the gynecology indication is. It is CE-marked and commercial across Europe, Latin America, AMEA, and Australia. As enterprise B2B surgical equipment sold to hospitals, there is no consumer price.

da Vinci (and Ion)

Intuitive Surgical's da Vinci is the gold-standard surgical robot and the verified-at-scale anchor of the category. Per Intuitive's SEC filings, 11,395 da Vinci systems and 1,041 Ion endoluminal systems are installed. The lineup spans da Vinci multi-port (X/Xi), the single-port SP, and the fifth-generation da Vinci 5 (FDA cleared March 2024, with force feedback), plus the Ion bronchoscopy robot (FDA 2019).

It is teleoperated, a surgeon controls every motion, with shipped analytics AI; autonomous-suturing work exists only as research demos on da Vinci hardware, not as shipped product. It is enterprise B2B equipment sold to hospitals at multi-million-dollar per-system prices; there is no consumer price.

Common questions

How do Versius and da Vinci (and Ion) differ?

On DEPLOY's record, da Vinci (and Ion) is further along: at the production stage versus Versius at the commercial stage, as of 2026. Versius has the lower recorded price. da Vinci (and Ion) has more verified real-world deployments (13 vs 4). Versius is at the commercial stage; da Vinci (and Ion) at the production stage.

What is the difference between Versius and da Vinci (and Ion)?

Versius and da Vinci (and Ion) are both surgical robots on the DEPLOY registry. They differ in maker, maturity, price, verified deployments, and how much of their autonomy is independently verified. See the table above for the full head-to-head; each figure is sourced.

Which is cheaper, Versius or da Vinci (and Ion)?

Versius has the lower recorded price on the DEPLOY registry than da Vinci (and Ion). Prices are sourced; see each record for whether the figure is a manufacturer target, an estimate, or an actual sale price.

Is Versius or da Vinci (and Ion) more autonomous?

On the DEPLOY registry, neither Versius nor da Vinci (and Ion) has capabilities independently verified as fully autonomous yet; their recorded capabilities are teleoperated-assisted, demonstrated, or vendor-claimed. See the table for each capability's verification status.

Which has more verified deployments, Versius or da Vinci (and Ion)?

da Vinci (and Ion) has more verified deployments (13) on the DEPLOY registry than Versius (4). DEPLOY counts a deployment only when confirmed at a named site with a primary source.

Recent coverage

Surgeons use da Vinci surgical robot to perform common cardiac surgeryda Vinci (and Ion) · The Robot Report · 2026-08-17
Da Vinci 5 Cleared for Cardiac Proceduresda Vinci (and Ion) · isrg.intuitive.com · 2026-07-26
CMR Surgical secures 510k clearance of Versius Plus robotic surgical systemVersius · Ben Smith, Deploy Editor · 2026-06-09
FDA Clears New Robotic Platform for Gallbladder SurgeryVersius · Ben Smith, Deploy Editor · 2025-12-17

Related comparisons

Keep researching

Keep reading

All surgical robotsRegistry Every verified record in the category.VersiusModel The full model page.da Vinci (and Ion)Model The full model page.CMR SurgicalRecord The maker's verified record.Intuitive SurgicalRecord The maker's verified record.Versius vs Stryker Mako SmartRoboticsCompare Another head-to-head.

Ask the registry

For AI assistants

Use DEPLOY in Claude, Cursor, and other AI assistants

Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.

Install instructions Download for Claude Desktop

Machine-readable: this page as markdown.

← Back to all consumer robots